Download INTERNATIONAL CONFERENCE ON CANCER CARE AND CURE

i
INTERNATIONAL CONFERENCE ON
CANCER CARE AND CURE
Nanomed - 2016
Nov e mbe r 2 8-29, 20 1 6
https://www.clytoaccess.com/world-summit-nanotechnology-and-nanomedicine-research
Dubai
KEYNOTE SPEAKER
G.P. Talwar
Founder and Director, National Institute of
Immunlogy, India
Immunotherapy of Advanced stage invariably Drugs Resistant Cancers
BIOGRAPHYG. P. Talwar is a medical researcher working in
the area of vaccines and immunocontraception.
He received BSc (Hons) and MSc (Tech) degrees
from the University of Punjab; DSc from Sorbonne
working at the Institute Pasteur, Paris and DSc (hc)
from Bundhelkhand University .He was Alexander
von Humboldt Postdoctoral Fellow at Tübingen,
Stuttgart and Munchen. He joined as Associate
Professor of Biochemistry in the newly created All
India Institute of Medical Sciences (AIIMS), New
Delhi and also worked there as Professor and Head.
He was Head, ICMR-WHO Research and Training
Centre in Immunology for India and South East Asia
(1972–91). He was the first Director of the National
Institute of Immunology (NII). He was Professor
of Eminence and Senior Consultant, International
Centre for Genetic Engineering and Biotechnology
(ICGEB), New Delhi and Director Research, Talwar
Research Foundation, New Delhi, India.
ABSTRACT-
Cancer is accounting for increasing number of
deaths in all countries. If detected at an early
stage, it can be surgically removed. Radiations and
a fairly large number of drugs are available to take
care of most cancers. However a stage arrives in
many cancers that residual Drugs-resistant cancer
emerges. It is metastasized, hence not removable
surgically, nor controllable by radiations. At this
advanced stage, many cancers start expressing
ectopically the embryonic hormone hCG. Data will
be presented to show that Monoclonal antibodies
against hCG can be employed to kill cancer cells,
such as those of lung cancer. Some cancer cells such
as those of Molt-4 lymphoblastic leukemia express
hCG, but are not killed by anti-hCG antibodies alone
or in presence of Complement. These cancer cells
are completely eliminated by using the antibody
conjugated to Curcumin, a totally safe compound.
Therapeutic antibodies are expensive for repeated
intake. These require backing by a Vaccine evoking
potent anti-hCG response. We have developed a
highly immunogenic recombinant Vaccine against
hCG, which is amenable to industrial production for
unlimited supply. Also a highly useful and already
approved Vaccine by DCGI and USFDA is available.
It is based on Mycobacterium indicus pranii (MIP),
which has both preventive and therapeutic action
against Myelomas and other cancers and is being
used by Clinicians in India as djunct to other
therapies for cancers. It is a potent invigorator of
both humoral and cellular immune response.